GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (FRA:RER1) » Definitions » EV-to-FCF

Recordati SpA (FRA:RER1) EV-to-FCF : 24.87 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Recordati SpA EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Recordati SpA's Enterprise Value is €11,778 Mil. Recordati SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €474 Mil. Therefore, Recordati SpA's EV-to-FCF for today is 24.87.

The historical rank and industry rank for Recordati SpA's EV-to-FCF or its related term are showing as below:

FRA:RER1' s EV-to-FCF Range Over the Past 10 Years
Min: -4355.39   Med: 25.58   Max: 123.9
Current: 24.87

During the past 13 years, the highest EV-to-FCF of Recordati SpA was 123.90. The lowest was -4355.39. And the median was 25.58.

FRA:RER1's EV-to-FCF is ranked better than
50.73% of 550 companies
in the Drug Manufacturers industry
Industry Median: 25.795 vs FRA:RER1: 24.87

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), Recordati SpA's stock price is €50.70. Recordati SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €2.023. Therefore, Recordati SpA's PE Ratio (TTM) for today is 25.06.


Recordati SpA EV-to-FCF Historical Data

The historical data trend for Recordati SpA's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA EV-to-FCF Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.39 37.60 30.63 25.71 114.12

Recordati SpA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.45 114.12 78.14 101.17 24.89

Competitive Comparison of Recordati SpA's EV-to-FCF

For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Recordati SpA's EV-to-FCF falls into.



Recordati SpA EV-to-FCF Calculation

Recordati SpA's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11778.146/473.615
=24.87

Recordati SpA's current Enterprise Value is €11,778 Mil.
Recordati SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €474 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA  (FRA:RER1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Recordati SpA's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=50.70/2.023
=25.06

Recordati SpA's share price for today is €50.70.
Recordati SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Recordati SpA EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Recordati SpA's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA Business Description

Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.

Recordati SpA Headlines

No Headlines